

Fund Overview

This Semi-annual shareholder report contains important information about the ProFund VP Biotechnology (the "Fund") for the period of January 1, 2025 to June 30, 2025. You can find additional information about the Fund at www.profunds.com/literature/profunds-variable-products. You can also request this information by contacting us at 888-776-3637.

What were the Fund's costs for the last six months?

(based on a hypothetical \$10,000 investment)

Fund Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
ProFund VP Biotechnology	\$77	1.63%

Fund Statistics	
Net Assets	\$29,058,669
Number of Holdings*	130
Net Investment Advisory Fees	\$119,071
Portfolio Turnover	125%

* No. of Holdings excludes any derivatives and collateral for securities loaned.

Largest Sector Weights	
Sector	
Biotechnology	100%

Market Exposure	
Investment Type	% of Net Assets
Equity Securities	99%
S&P Biotechnology Select Industry Index Swap Agreements	1%
Total	100%

Largest Equity Holdings	
Holding	% of Net Assets
Alnylam Pharmaceuticals, Inc.	2.6%
Exelixis, Inc.	2.6%
United Therapeutics Corp.	2.5%
Insmmed, Inc.	2.5%
Gilead Sciences, Inc.	2.4%

"Market Exposure" includes the value of total investments (including the contract value of any derivatives) and excludes any short-term investments and instruments used for cash management.

ProFund VP Biotechnology



Semi-annual Shareholder Report – June 30, 2025

Additional information about the Fund including the Financial Statements, Prospectus and Statement of Additional Information is available: On the Fund's website, www.profunds.com/literature/profunds-variable-products, or upon request, by calling 888-776-3637.